Drug Information

Drug General Information
Drug ID
D06BKH
Former ID
DIB009472
Drug Name
GR-MD-02
Indication Melanoma [ICD9: 172; ICD10:C43] Phase 2 [525159]
Company
Galectin therapeutics
Target and Pathway
Target(s) Galectin-3 Target Info Inhibitor [532604]
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database Hedgehog signaling events mediated by Gli proteins
Regulation of Ras family activation
Reactome Advanced glycosylation endproduct receptor signaling
WikiPathways Spinal Cord Injury
AGE/RAGE pathway
Advanced glycosylation endproduct receptor signaling
References
Ref 525159ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health.
Ref 532604Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.